Budget Impact Evaluation Of A Vaccination With Campaign Program For Corporations Using Pneumococcal Conjugated Vaccine (Pcv) 13 Valent Versus Pneumococcal Polisaccharide Vaccine (Ppv) 23 With Paid Campaign For Older Adults

May 1, 2013, 00:00
10.1016/j.jval.2013.03.390
https://www.valueinhealthjournal.com/article/S1098-3015(13)00461-0/fulltext
Title : Budget Impact Evaluation Of A Vaccination With Campaign Program For Corporations Using Pneumococcal Conjugated Vaccine (Pcv) 13 Valent Versus Pneumococcal Polisaccharide Vaccine (Ppv) 23 With Paid Campaign For Older Adults
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)00461-0&doi=10.1016/j.jval.2013.03.390
First page : A84
Section Title : Infection
Open access? : No
Section Order : 1433
Categories :
Tags :
Regions :
ViH Article Tags :